Martin Hoenigl, IDWeek 2022: Guideline adherence predicts outcomes of candidemia in Europe
In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss ECMM Candida III Multinational European study, which collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe, to assess how adherence to guideline recommendations correlate with outcomes.
The abstract entitled: ‘Guideline Adherence Predicts Outcomes of Candidemia in Europe: Results from the ECMM Candida III Multinational European study’ was presented at IDWeek 2022, 19-23 October 2022.
Interviews available in this series:
Candidemia prognosis and unmet needs in its treatment
Guideline adherence predicts outcomes of candidemia in Europe
- What were the objectives and methodology of your study? (0:12)
- How did guideline adherence impact mortality and hospitalisation? (1:43)
- What were the conclusions of the investigators? (3:40)
Disclosures: Martin Hoenigl is a consultant for Scynexis, Pulmocide, Gilead, Euro Pharma Holings, and Mundipharma; receives grant/research support from Gilead, Scynexis, Pfizer, MSD, Euroimun, and Mundipharma; and is on the advisory board for F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Fungal Infections
Ibrexafungerp against Mucor strains using time-kill and scanning electron microscopy: ECCMID 2023, Mahmoud Ghannoum
Vulnerable immunocompromised individuals are at risk of opportunistic infections by invasive molds, and available antifungal treatments for these invasive infections are currently restricted. Therefore, a combination of therapies has been proposed as a potential strategy to enhance the effectiveness of treatment outcomes. Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals Cleveland Medical Centre, […]
Antifungal resistance – biofilms, tolerance phenomena, treatment and diagnostics: Mahmoud Ghannoum, ECCMID, 2023
Antifungal resistance is an increasing concern in the treatment of fungal infections, especially when there are already limited options in the treatment paradigm. It was a pleasure to talk with Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Center for Medical Mycology, Cleveland, OH, USA) around the impact of biofilms on antifungal therapy, […]
ECCMID 2023 highlights in fungal infections – diagnostics, treatments and case reports: Mahmoud Ghannoum
Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Centre for Medical Mycology, Cleveland, OH, USA) joins us to discuss ECCMID 2023 highlights in fungal infections, antifungal therapies, diagnostic approaches, and specific case reports that help advise clinicians in clinical practice. Interviews in this series: Ibrexafungerp against Mucor strains using time-kill and scanning electron […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!